Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 1
2005 1
2007 2
2011 2
2014 1
2015 2
2016 1
2019 1
2020 1
2021 4
2022 5
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Bowman SJ, et al. Among authors: grader beck t. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30. Lancet. 2022. PMID: 34861168 Clinical Trial.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: grader beck t. Arthritis Rheumatol. 2025 May;77(5):560-570. doi: 10.1002/art.43059. Epub 2025 Jan 5. Arthritis Rheumatol. 2025. PMID: 39557617 Clinical Trial.
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W; TWINSS study group. Fisher BA, et al. Among authors: grader beck t. Lancet. 2024 Aug 10;404(10452):540-553. doi: 10.1016/S0140-6736(24)01211-X. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096929 Clinical Trial.
Clinical Characteristics of Hydralazine-induced Lupus.
Timlin H, Wu M, Crespo-Bosque M, Geetha D, Ingolia A, Haque U, Towns MC, Grader-Beck T. Timlin H, et al. Among authors: grader beck t. Cureus. 2019 Jun 25;11(6):e4996. doi: 10.7759/cureus.4996. Cureus. 2019. PMID: 31497427 Free PMC article.
Ocular complications of primary Sjögren syndrome in men.
Mathews PM, Hahn S, Hessen M, Kim J, Grader-Beck T, Birnbaum J, Baer AN, Akpek EK. Mathews PM, et al. Among authors: grader beck t. Am J Ophthalmol. 2015 Sep;160(3):447-452.e1. doi: 10.1016/j.ajo.2015.06.004. Epub 2015 Jun 17. Am J Ophthalmol. 2015. PMID: 26093285
23 results